Metsera To Present At TD Cowen’S 45Th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com . A replay of the webcast will be available for ...
The Crypto Basic on MSN5h
Bitcoin Adoption Rallies as 80% More Public Companies Bought in 2024: Report
The rate at which corporate and private institutions adopt the Bitcoin standard has surged extensively in the past year as ...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Investing1d
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug ...
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metsera initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
Metsera initiated with a Buy at BofA
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
https//beincrypto.com2d
MicroStrategy Makes its Largest Bitcoin Purchase of 2025 at Nearly $2 Billion
Michael Saylor buys 20,356 BTC for $1.99 billion, funding purchases with stock sales as shares drop 16%. Bitcoin's slump adds more risk.
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...